# Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

> **NCT04916509** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 258 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Palbociclib plus an aromatase inhibitor
- **DRUG:** Palbociclib plus fulvestrant

## Key facts

- **NCT ID:** NCT04916509
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-13
- **Primary completion:** 2022-12-27
- **Final completion:** 2022-12-27
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916509, "Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04916509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*